New hope for EoE patients: expanded access to APT-1011
Disease control
NO_LONGER_AVAILABLE
This program provides early access to APT-1011, a swallowed steroid tablet, for people aged 12 and older with eosinophilic esophagitis (EoE) who cannot join other studies or have not responded to available treatments. The goal is to offer a potential treatment option until the dr…
Sponsor: Ellodi Pharmaceuticals, LP • Aim: Disease control
Last updated May 17, 2026 09:10 UTC